Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Amelogenin X-linked (AMELX) is a gene encoding the major form of the protein amelogenin, an extracellular matrix protein essential for the formation of tooth enamel[1][2][3][4][5][6]. Amelogenin comprises about 90% of the protein in developing enamel and is responsible for the regulation, organization, and mineralization of enamel crystallites during tooth development, ensuring proper enamel structure and strength[1][2][3][5]. Mutations in AMELX cause X-linked forms of amelogenesis imperfecta, a group of inherited conditions characterized by abnormally formed or hypomineralized enamel, which can result in fragile, discolored, or grooved teeth[2][4][5]. Although AMELX primarily functions in enamel, lower levels are also found in other tissues, but their biological significance there is not fully understood[5]. AMELX is not considered a direct drug target, and there are no known drugs acting on this protein. However, AMELX status is a useful genetic biomarker for certain dental disorders and for sex determination in forensic analysis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Amelogenin X-linked (AMELX).